In addition, in order to confirm whether VEC-PD-L1 had a role on the efficacy of anlotinib, we injected bEnd.3 (−) or CD274-bEnd.3 (+) cells intratumorally into tumor tissues separately with anlotinib treatment. This evidence concerns the gene CD274 and neoplasm.